HemodialysisNCT06695923
Different Ultrafiltration Rates and Intradialytic Hypotension.
An observational study of Hemodialysis and Intradialytic Hypotension, run by Sohag University at 1 site in Egypt.
Trial summary
Finding relationship between different ultrafiltration rates and intradialytic hypotension in attempt to find the optimal cut off points. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hemodialysis, Intradialytic Hypotension
- How many people
- 50 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Feb 2025to 1 Jan 2026
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Hemodialysis patients more than 18 year old on maintenance hemodialysis receiving 3 sessions weekly.
Who may be able to join
- All patients aged 18 Year or older on maintenance haemodialysis for at least 3 consecutive months receiving 3 sessions weekly.
- -
Who cannot join
- Patients aged < 18 years old.
- Patients on recent haemodialysis < 3 months.
- Pregnant women.
- Patients with malignancy, severe infections or sepsis.
- Patients with major bleeding.
- Patients who cannot go upper limb monitoring of blood pressure.
- Patients with severe heart failure (NYHA) class 3 or more.
- Patients with severe anemia, Hemoglobin less than 6 g/dl.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Association of Ultrafiltration Rates and Intradialytic Hypotension in Sohag University Hospitals.
Finding relationship between different ultrafiltration rates and intradialytic hypotension in attempt to find the optimal cut off points.
Read the detailed description
This observational study will be carried upon hemodialysis patients with different ultrafiltration rates at each session to study the association between ultrafiltration rates and intradialytic hypotension.
Thus identifying the optimal cut off of ultrafiltration rate points for each patient
- Conditions
- Hemodialysis, Intradialytic Hypotension
- Keywords
- Ultrafiltration rates, Intradialytic hypotension
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevent Intradialytic Hypotension
Finding the optimal threshold of ultrafiltration rates to prevent intradialytic hypotension through observing the risk factors associated with the occurrence of HDH
Measured: 6 month
Clinical History Among the Study Patients.
Analysis of the prevalence of chronic illness among the study participants, as well as the number of antihypertensive drugs used.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Nov 2024
- Study start1 Feb 2025
- Primary completion1 Dec 2025
- Study completion1 Jan 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for HemodialysisStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 50 participants (actual)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marwa Mahmoud Gad, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06695923
- Sponsor's protocol ID
- Soh-Med--24-11-12MS
- Status last verified
- Feb 2026
- First submitted
- 15 Nov 2024
- Last updated
- 2 Mar 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Association of Ultrafiltration Rates and Intradialytic Hypotension in Sohag University Hospitals.
- ClinicalTrials.gov ID
- NCT06695923
- Acronym / sponsor ID
- Soh-Med--24-11-12MS
- Conditions
- Hemodialysis, Intradialytic Hypotension
- Keywords
- Ultrafiltration rates, Intradialytic hypotension
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 50 participants (actual)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Feb 2025 (actual)
- Primary completion
- 1 Dec 2025 (actual)
- Study completion
- 1 Jan 2026 (actual)
- First posted
- 19 Nov 2024 (actual)
- Results
- Posted 2 Mar 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Finding relationship between different ultrafiltration rates and intradialytic hypotension in attempt to find the optimal cut off points.
Detailed description
This observational study will be carried upon hemodialysis patients with different ultrafiltration rates at each session to study the association between ultrafiltration rates and intradialytic hypotension.
Thus identifying the optimal cut off of ultrafiltration rate points for each patient
Study design
- Observational model
- Case-control
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Hemodialysis patients more than 18 year old on maintenance hemodialysis receiving 3 sessions weekly.
Key inclusion criteria (2 listed)
- All patients aged 18 Year or older on maintenance haemodialysis for at least 3 consecutive months receiving 3 sessions weekly.
- -
Key exclusion criteria (8 listed)
- Patients aged < 18 years old.
- Patients on recent haemodialysis < 3 months.
- Pregnant women.
- Patients with malignancy, severe infections or sepsis.
- Patients with major bleeding.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevent Intradialytic Hypotension
Time frame: 6 month
Finding the optimal threshold of ultrafiltration rates to prevent intradialytic hypotension through observing the risk factors associated with the occurrence of HDH
Clinical History Among the Study Patients.
Time frame: 6 months
Analysis of the prevalence of chronic illness among the study participants, as well as the number of antihypertensive drugs used.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Undecided
Related trials for Hemodialysis
Not yet recruiting
Manual Acupuncture for Intradialytic Nausea and Vomiting in Patients Undergoing Hemodialysis
Intradialytic Nausea and Vomiting, Chronic Kidney Disease
RecruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
RecruitingPhase 1
A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis
End Stage Renal Disease on Dialysis, Adult
Not yet recruitingPhase 1/2
Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis
End Stage Renal Disease, Fatigue
Active, not recruiting
Group Exercise Program Supported By Audiovisual Media During Hemodialysis
Chronic Kidney Failure, Hemodialysis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hemodialysis and Intradialytic Hypotension, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 2 Mar 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevent Intradialytic Hypotension (time frame: 6 month). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2026.